Phase i trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer

Tufia C. Haddad, Antonino D’Assoro, Vera Suman, Mateusz Opyrchal, Prema Peethambaram, Minetta C. Liu, Matthew P. Goetz, James N. Ingle

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences